PT  - JOURNAL ARTICLE
AU  - TAKASHI NAGAI
AU  - TAKU NAIKI
AU  - TERUKI ISOBE
AU  - YOSUKE SUGIYAMA
AU  - TOSHIKI ETANI
AU  - KEITARO IIDA
AU  - SATOSHI NOZAKI
AU  - YUSUKE NODA
AU  - NOBUHIKO SHIMIZU
AU  - YOSHIHIKO TASAKI
AU  - YOSHIHISA MIMURA
AU  - RIKA BANNO
AU  - HIROKI KUBOTA
AU  - SHUZO HAMAMOTO
AU  - NORIYASU KAWAI
AU  - TAKAHIRO YASUI
TI  - Modified Glasgow Prognostic Score 2 as a Prognostic Marker in Patients With Metastatic Urothelial Carcinoma
AID  - 10.21873/invivo.12565
DP  - 2021 Sep 01
TA  - In Vivo
PG  - 2793--2800
VI  - 35
IP  - 5
4099  - http://iv.iiarjournals.org/content/35/5/2793.short
4100  - http://iv.iiarjournals.org/content/35/5/2793.full
SO  - In Vivo2021 Sep 01; 35
AB  - Background/Aim: Predicting the prognosis of metastatic urothelial carcinoma (mUC) patients is needed for clinical decisions. We examined the value of a modified Glasgow prognostic score (mGPS) as a predictive marker for mUC patients. Patients and Methods: In a multicenter study, 68 mUC patients received short hydration gemcitabine/cisplatin (shGC) and 74 received pembrolizumab (PEM). Patients were allocated according to mGPS. Progression-free (PFS) and cancer-specific (CSS) survival were examined. Results: Higher mGPS reflected poorer PFS and CSS in shGC (p=0.03, p<0.0001, respectively) and PEM (p=0.02, p<0.001, respectively) patients. PFS for the high mGPS group was longer than that of the low mGPS group in the two cohorts (p <0.0001 for both), with similar CSS results (p<0.0001 and p<0.001, respectively). Multivariate analyses revealed high mGPS was a risk factor for poor CSS in both cohorts (HR=3.55, p<0.001, and HR=2.21, p<0.01, respectively). Conclusion: In the mUC patients receiving shGC or PEM, mGPS was a predictive prognostic marker.